US2014086996A1PendingUtilityA1

Water-soluble drug carrier and process for producing the same

53
Assignee: UNIV KYUSHU NAT UNIV CORPPriority: Jul 9, 2009Filed: Jul 22, 2013Published: Mar 27, 2014
Est. expiryJul 9, 2029(~3 yrs left)· nominal 20-yr term from priority
Inventors:Masahiro GotoNoriho KamiyaYoshiro Tahara
A61K 38/164A61K 9/113A61K 9/5073A61K 31/196A61K 31/728C12N 2810/859C12N 15/88C12N 2810/10A61K 9/5089A61K 31/721A61K 31/715A61K 47/62A61K 47/6907A61K 31/74A61K 31/713A61K 47/26A61K 47/24A61K 47/32A61K 31/7088A61K 47/183
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An object of the present invention is to provide a drug delivery carrier that is free from the drug leakage problem and has an easily controllable particle size, and that can be used to deliver water-soluble drugs such as genes and proteins in a wide range of applications, including delivery of water-soluble drugs that do not have high anionic properties, and also can be used as a non-viral gene vector. The invention also provides a process for production of such drug delivery carriers. The drug delivery carrier of the present invention includes a water-soluble drug double-coated with two types of inner and outer surfactants 1 and 2.

Claims

exact text as granted — not AI-modified
1 . A drug delivery carrier that comprises a water-soluble drug double-coated with two types of inner and outer surfactants 1 and 2. 
     
     
         2 . The drug delivery carrier according to  claim 1 , wherein the water-soluble drug is any one of protein, gene, oligonucleic acid, polysaccharide, synthetic polymer, peptide, small molecule, and nanoparticle (ultrastructure). 
     
     
         3 . The drug delivery carrier according to  claim 2 , wherein the gene is a pDNA, and wherein the protein is an EGFP. 
     
     
         4 . The drug delivery carrier according to  claim 1 , wherein the inner surfactant 1 is any one of sucrose fatty acid ester, cholesterol, and glycerin fatty acid ester. 
     
     
         5 . The drug delivery carrier according to  claim 1 , wherein the outer surfactant 2 is at least one of PC, L-1695, PEG(2K)-MS, PEG(2K)-DSPE, PEG(5K)-DSPE, PEG(comb)-DSPE, Tween 80, sodium dodecyl sulfate, and glycerin fatty acid ester. 
     
     
         6 . The drug delivery carrier according to  claim 1 , wherein the drug delivery carrier includes at least one of hydrophobic molecules such as DOPE and dinitrochlorobenzene, and cationic polymers such as PEI and poly-L-lysine. 
     
     
         7 . The drug delivery carrier according to  claim 1 , wherein the drug delivery carrier is modified on the outside by a cell membrane protein binding domain, including alkylated transmembrane peptides (for example, such as stearyl octaarginine R8-str, and stearyl tetraarginine R4-str), N-hydroxysuccinimide-PEG(2K)-DSPE, N-maleimide-PEG(2K)-DSPE, N-hydroxysuccinimide-PEG(2K)-DSPE, and antibodies, saquinavir, and hyaluronic acid modified by these. 
     
     
         8 - 12 . (canceled) 
     
     
         13 . The drug delivery carrier according to  claim 2 , wherein the inner surfactant 1 is any one of sucrose fatty acid ester, cholesterol, and glycerin fatty acid ester. 
     
     
         14 . The drug delivery carrier according to  claim 3 , wherein the inner surfactant 1 is any one of sucrose fatty acid ester, cholesterol, and glycerin fatty acid ester. 
     
     
         15 . The drug delivery carrier according to  claim 2 , wherein the outer surfactant 2 is at least one of PC, L-1695, PEG(2K)-MS, PEG(2K)-DSPE, PEG(5K)-DSPE, PEG(comb)-DSPE, Tween 80, sodium dodecyl sulfate, and glycerin fatty acid ester. 
     
     
         16 . The drug delivery carrier according to  claim 3 , wherein the outer surfactant 2 is at least one of PC, L-1695, PEG(2K)-MS, PEG(2K)-DSPE, PEG(5K)-DSPE, PEG(comb)-DSPE, Tween 80, sodium dodecyl sulfate, and glycerin fatty acid ester. 
     
     
         17 . The drug delivery carrier according to  claim 4 , wherein the outer surfactant 2 is at least one of PC, L-1695, PEG(2K)-MS, PEG(2K)-DSPE, PEG(5K)-DSPE, PEG(comb)-DSPE, Tween 80, sodium dodecyl sulfate, and glycerin fatty acid ester. 
     
     
         18 . The drug delivery carrier according to  claim 2 , wherein the drug delivery carrier includes at least one of hydrophobic molecules such as DOPE and dinitrochlorobenzene, and cationic polymers such as PEI and poly-L-lysine. 
     
     
         19 . The drug delivery carrier according to  claim 3 , wherein the drug delivery carrier includes at least one of hydrophobic molecules such as DOPE and dinitrochlorobenzene, and cationic polymers such as PEI and poly-L-lysine. 
     
     
         20 . The drug delivery carrier according to  claim 4 , wherein the drug delivery carrier includes at least one of hydrophobic molecules such as DOPE and dinitrochlorobenzene, and cationic polymers such as PEI and poly-L-lysine. 
     
     
         21 . The drug delivery carrier according to  claim 5 , wherein the drug delivery carrier includes at least one of hydrophobic molecules such as DOPE and dinitrochlorobenzene, and cationic polymers such as PEI and poly-L-lysine. 
     
     
         22 . The drug delivery carrier according to  claim 2 , wherein the drug delivery carrier is modified on the outside by a cell membrane protein binding domain, including alkylated transmembrane peptides (for example, such as stearyl octaarginine R8-str, and stearyl tetraarginine R4-str), N-hydroxysuccinimide-PEG(2K)-DSPE, N-maleimide-PEG(2K)-DSPE, N-hydroxysuccinimide-PEG(2K)-DSPE, and antibodies, saquinavir, and hyaluronic acid modified by these. 
     
     
         23 . The drug delivery carrier according to  claim 3 , wherein the drug delivery carrier is modified on the outside by a cell membrane protein binding domain, including alkylated transmembrane peptides (for example, such as stearyl octaarginine R8-str, and stearyl tetraarginine R4-str), N-hydroxysuccinimide-PEG(2K)-DSPE, N-maleimide-PEG(2K)-DSPE, N-hydroxysuccinimide-PEG(2K)-DSPE, and antibodies, saquinavir, and hyaluronic acid modified by these. 
     
     
         24 . The drug delivery carrier according to  claim 4 , wherein the drug delivery carrier is modified on the outside by a cell membrane protein binding domain, including alkylated transmembrane peptides (for example, such as stearyl octaarginine R8-str, and stearyl tetraarginine R4-str), N-hydroxysuccinimide-PEG(2K)-DSPE, N-maleimide-PEG(2K)-DSPE, N-hydroxysuccinimide-PEG(2K)-DSPE, and antibodies, saquinavir, and hyaluronic acid modified by these. 
     
     
         25 . The drug delivery carrier according to  claim 5 , wherein the drug delivery carrier is modified on the outside by a cell membrane protein binding domain, including alkylated transmembrane peptides (for example, such as stearyl octaarginine R8-str, and stearyl tetraarginine R4-str), N-hydroxysuccinimide-PEG(2K)-DSPE, N-maleimide-PEG(2K)-DSPE, N-hydroxysuccinimide-PEG(2K)-DSPE, and antibodies, saquinavir, and hyaluronic acid modified by these.

Join the waitlist — get patent alerts

Track US2014086996A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.